A case of multi-agent drug resistant choriocarcinoma treated with Pembrolizumab

• High-risk multi-agent drug resistant GTN is a life threatening disease. • Majority of choriocarcinomas show intense PD-L1 immunoreactivity. • Pembrolizumab increases antitumor activity. • Effectiveness of Pembrolizumab in treating patients with high-risk multi-agent drug resistant GTN.

Detalles Bibliográficos
Autores principales: Goldfarb, Jennifer A., Dinoi, Giorgia, Mariani, Andrea, Langstraat, Carrie L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210394/
https://www.ncbi.nlm.nih.gov/pubmed/32395603
http://dx.doi.org/10.1016/j.gore.2020.100574
_version_ 1783531265151991808
author Goldfarb, Jennifer A.
Dinoi, Giorgia
Mariani, Andrea
Langstraat, Carrie L.
author_facet Goldfarb, Jennifer A.
Dinoi, Giorgia
Mariani, Andrea
Langstraat, Carrie L.
author_sort Goldfarb, Jennifer A.
collection PubMed
description • High-risk multi-agent drug resistant GTN is a life threatening disease. • Majority of choriocarcinomas show intense PD-L1 immunoreactivity. • Pembrolizumab increases antitumor activity. • Effectiveness of Pembrolizumab in treating patients with high-risk multi-agent drug resistant GTN.
format Online
Article
Text
id pubmed-7210394
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-72103942020-05-11 A case of multi-agent drug resistant choriocarcinoma treated with Pembrolizumab Goldfarb, Jennifer A. Dinoi, Giorgia Mariani, Andrea Langstraat, Carrie L. Gynecol Oncol Rep Case Report • High-risk multi-agent drug resistant GTN is a life threatening disease. • Majority of choriocarcinomas show intense PD-L1 immunoreactivity. • Pembrolizumab increases antitumor activity. • Effectiveness of Pembrolizumab in treating patients with high-risk multi-agent drug resistant GTN. Elsevier 2020-04-23 /pmc/articles/PMC7210394/ /pubmed/32395603 http://dx.doi.org/10.1016/j.gore.2020.100574 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Goldfarb, Jennifer A.
Dinoi, Giorgia
Mariani, Andrea
Langstraat, Carrie L.
A case of multi-agent drug resistant choriocarcinoma treated with Pembrolizumab
title A case of multi-agent drug resistant choriocarcinoma treated with Pembrolizumab
title_full A case of multi-agent drug resistant choriocarcinoma treated with Pembrolizumab
title_fullStr A case of multi-agent drug resistant choriocarcinoma treated with Pembrolizumab
title_full_unstemmed A case of multi-agent drug resistant choriocarcinoma treated with Pembrolizumab
title_short A case of multi-agent drug resistant choriocarcinoma treated with Pembrolizumab
title_sort case of multi-agent drug resistant choriocarcinoma treated with pembrolizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210394/
https://www.ncbi.nlm.nih.gov/pubmed/32395603
http://dx.doi.org/10.1016/j.gore.2020.100574
work_keys_str_mv AT goldfarbjennifera acaseofmultiagentdrugresistantchoriocarcinomatreatedwithpembrolizumab
AT dinoigiorgia acaseofmultiagentdrugresistantchoriocarcinomatreatedwithpembrolizumab
AT marianiandrea acaseofmultiagentdrugresistantchoriocarcinomatreatedwithpembrolizumab
AT langstraatcarriel acaseofmultiagentdrugresistantchoriocarcinomatreatedwithpembrolizumab
AT goldfarbjennifera caseofmultiagentdrugresistantchoriocarcinomatreatedwithpembrolizumab
AT dinoigiorgia caseofmultiagentdrugresistantchoriocarcinomatreatedwithpembrolizumab
AT marianiandrea caseofmultiagentdrugresistantchoriocarcinomatreatedwithpembrolizumab
AT langstraatcarriel caseofmultiagentdrugresistantchoriocarcinomatreatedwithpembrolizumab

Ejemplares similares